Ivermectin Glenmark

Ivermectin, the active ingredient in Ivermectin Glenmark, is an anthelmintic (macrocyclic lactone) presented as a tablet for oral use. It treats a range of parasitic worm infections and ectoparasitic skin conditions in adults and children as prescribed by a healthcare professional.

GNH USA supplies Ivermectin Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivermectin is an antiparasitic agent used to treat infections caused by various helminths and ectoparasites. - Onchocerciasis: reduces microfilarial load and helps control disease progression. - Strongyloidiasis: eliminates intestinal larvae and prevents disseminated infection. - Scabies: eradicates Sarcoptes scabiei mites, relieving itching and skin lesions. - Lymphatic filariasis: decreases adult worm burden and interrupts transmission. - Other helminth infections: provides broad‑spectrum activity against several nematode species.

Ivermectin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: transient light‑headedness. - Pruritus: itching at the site of parasite death. - Headache: mild tension‑type headache. - Abdominal pain: cramping or discomfort. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Hepatotoxicity: elevated liver enzymes or jaundice. - Neurologic toxicity: seizures or altered mental status. - Anaphylaxis: acute allergic reaction with respiratory compromise. - Severe hypotension: sudden drop in blood pressure. - Visual disturbances: blurred vision or optic neuritis.

Before prescribing Ivermectin, clinicians should consider several safety measures. - Assess contraindications: avoid use in patients with known hypersensitivity to ivermectin. - Review patient history: consider coexisting liver disease or neurologic disorders. - Monitor liver function: periodic testing may be warranted in long‑term therapy. - Avoid concomitant CNS depressants: may increase risk of neurologic side effects. - Consider drug interactions: evaluate other medications that affect CYP3A4 or P‑glycoprotein. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Ivermectin may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can raise ivermectin plasma concentrations. - P‑glycoprotein inhibitors (e.g., verapamil, quinidine): may increase systemic exposure.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Other antiparasitics: combined use can increase risk of neurotoxicity. - CNS depressants (e.g., benzodiazepines): may potentiate dizziness or sedation. - Antihistamines: could mask early signs of allergic reactions. - Immunosuppressants: may alter parasite clearance rates.